Menu
Menu
Whole-exome sequencing (WES) is widely used in both clinical and research settings, but current implementations require trade-offs between genomic breadth, sensitivity, and workflow complexity. As a result, labs typically maintain multiple assays to meet different kinds of testing.
In this GEN webinar, Guilherme Yamamoto, MD, PhD, and Sevana Yaghoubian will present a novel whole-exome assay for detecting high-confidence variants across multiple applications. Using examples from rare diseases, newborn and carrier screening, and targeted analysis for cardiovascular, neurological, ocular, and metabolic disorders, they will explore how combining targeted probe enhancements with robust analytics improves performance in challenging genomic regions. They will also discuss how these enhanced exome assays can extend beyond germline testing through secondary screening for common somatic variants in hematologic cancers. Key takeaways from the webinar include:
Speakers:
Guilherme Yamamoto, MD, PhD
Head of Genomics and Bioinformatics Innovation
Dasa
Sevana Yaghoubian, MSc
Senior Director Genomics
SOPHiA GENETICS
Speaker: Persephone du Parcq, Lead Clinical/Translational Scientist, Synnovis, UK
In this webinar, Dr. Persephone du Parcq shares how Synnovis has deployed the MSK-ACCESS™ powered with SOPHiA DDM™ to support precision oncology through minimally invasive liquid biopsy testing.
The webinar explores current clinical applications of ctDNA analysis, its demonstrated utility in routine healthcare, and key considerations around assay selection, validation strategies, and interpretation challenges including germline findings and clonal haematopoiesis. Practical insights into clinical impact, operational achievements to date, and lessons learned from clinical implementation are also discussed.
Finally, the session looks ahead to future directions for liquid biopsy in oncology, including opportunities to expand clinical adoption and improve patient care through advanced genomic technologies.
In this webinar, PD Dr. Daniel Kazdal, Head of Technology and Assay Development at the Center for Molecular Pathology, Universitätsklinikum Heidelberg, provides a practical overview of liquid biopsy testing in routine molecular diagnostics.
The session explores the clinical value of liquid biopsy, key challenges in result interpretation—particularly the impact of clonal hematopoiesis (CHIP) and real-world experience with decentralized MSK-ACCESS® testing powered by SOPHiA DDM™ at Heidelberg University Hospital. Through workflow insights and routine case examples, the webinar highlights how liquid biopsy supports accurate data interpretation and informed clinical decision-making, while also outlining future directions for its implementation in precision oncology.
Juan C. Gomez-Gelvez, MD
Section Head, Molecular Hematopathology — Henry Ford Health System
Measurable residual disease (MRD) represents the small number of leukemic cells that persist after treatment—undetectable by morphology yet clinically decisive. MRD status is now recognized as one of the strongest predictive and prognostic biomarkers in acute myeloid leukemia, influencing relapse risk, survival, and post-remission management.
In this on-demand session, Dr. Gomez-Gelvez walks through the principles, practicalities, and impact of using NGS to detect MRD with high sensitivity.
What You’ll Learn
Key Takeaways
Why Watch?
If you’re advancing AML diagnostics or shaping MRD strategies, this session provides clear, practical guidance from clinical concept through real-world application.
Healthcare institutions are under increasing pressure to manage multiple genomic workflows, each with its own unique technical and operational challenges. Disparate processes often create operational inefficiencies, increase costs, and limit the ability to scale precision oncology services.
In this webinar, Guy Froyen, senior NGS scientist, will discuss how Jessa Hospital, Belgium, is addressing these challenges by adopting the SOPHiA DDM™ Platform to harmonize NGS workflows across the hospital’s pathology operations. By standardizing processes — from library preparation through fully integrated analytics — they aim to maintain short turnaround times and streamline operations.
Froyen will highlight the hospital’s experience implementing MSK-IMPACT® Flex powered with SOPHiA DDM™, a modular solution for comprehensive genomic profiling that supports both agile and scalable solid tumor analysis.
Speakers:
Guy Froyen (PhD), Senior NGS Scientist, Jessa Hospital, Belgium
Traditional genomic analysis often requires sequential testing or a “one-size-fits-all” comprehensive genomic profiling (CGP) panel, leading to time-consuming workflows and increased costs. MSK-IMPACT® Flex powered with SOPHiA DDM™ is a modular, end-to-end CGP solution built on the expertly designed content of MSK-IMPACT®. The flexible design enables agile analysis and high-resolution profiling of complex biomarkers (including TMB, MSI, HRD, and gene- and exon-level CNVs) from DNA capture, RNA capture, and low-pass whole genome sequencing.
In this session, you will:
Speakers:
Dr. Rehan Mujeeb Faridi, PhD, HCLD/CC (ABB), Director of Molecular Diagnostics, OncoHelix
Lina Li, Director, Product Management, Application, SOPHiA GENETICS
Izabela Matyszczak, Technical Product Management Expert, SOPHiA GENETICS
Join us for an in-depth session on Alamut™ Visual Plus, an advanced variant interpretation software trusted by genetic research laboratories worldwide. This webinar will provide a comprehensive overview of the software’s capabilities—spanning intuitive visualization, integrated genomic annotations, splicing predictions, and ACMG classification support—designed to streamline and standardize variant review and interpretation.
Through a live demonstration, we’ll walk through key features and workflows that enable users to efficiently navigate NGS data, explore variant impacts in genomic context, and make evidence-based classification decisions. Whether you’re a new user seeking to understand the platform or an experienced user looking to optimize your analysis process, this session will showcase how Alamut™ Visual Plus empowers accurate and confident variant interpretation.
Speaker
Yi Lian - Product Director, Platform at SOPHiA GENETICS
The future of translational research and the most exciting advances are happening at the intersection of AI, multi-omics, biomarker development, and biospecimen strategy, each essential for capturing the biological variability that shapes precision medicine. This panel brings together scientists, technologists, and strategists driving the next generation of biomarker & diagnostic discovery and validation. You’ll hear from leaders at Precision for Medicine, SOPHiA GENETICS, and Olink, part of Thermo Fisher; partners at the forefront of multi-omics integration, AI-powered analytics, genomics and high-plex proteomics as they discuss leading-edge practices and where the field is headed in 2026.
Key Discussion Topics:
Who Should Attend:
Built for biotech, pharma, and diagnostic researchers who are shaping the next generation of precision medicine:
Speakers:
Deb Phippard Chief Scientific Officer, Precision for Medicine
Philippe Menu EVP, Chief Medical Officer & Chief Product Officer, SOPHiA GENETICS
Heng (Tony) Qian Head of Data Science (North America), Olink, part of Thermo Fisher Scientific
Rob Fannon Head of Biospecimen Solutions, Precision for Medicine
The Company finishes 2025 with strong Q4 performance, expects 20-22% revenue growth in 2026, and promotes Ross Muken to CEO
BOSTON and ROLLE, Switzerland, Jan. 12, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today provided preliminary unaudited financial results for the fourth quarter and full year 2025, initiated its financial outlook for 2026, and announced an executive transition plan, including the promotion of Ross Muken to Chief Executive Officer (CEO), effective July 1, 2026, and the transition of co-Founder Jurgi Camblong to Executive Chairman.
Fourth Quarter 2025 Preliminary Unaudited Financial Results
Full Year 2025 Preliminary Unaudited Financial Results
"2025 was a tremendous year for SOPHiA GENETICS as we reaccelerated revenue growth and materially exceeded our new business bookings target, setting the stage for robust future growth," said Jurgi Camblong, Chief Executive Officer of SOPHiA GENETICS. "Our strong performance in 2025 positions us well for continued growth in 2026 and beyond. Growth catalysts for the year ahead include our best-in-class Liquid Biopsy application MSK-ACCESS® powered with SOPHiA DDM™, valuable opportunities in the U.S. market, and a reinvigorated BioPharma business. We look forward to continuing to demonstrate operating leverage in 2026 and have high confidence in a material improvement in our financial position."
Full Year 2026 Guidance
Based on information as of today, SOPHiA GENETICS is providing the following FY 2026 guidance:
Executive Transition Plan
SOPHiA GENETICS today announced the promotion of Ross Muken to Chief Executive Officer, effective July 1, 2026. Mr. Muken, who currently serves as President and has been a key executive at the company for five years, will succeed Dr. Jurgi Camblong, co-founder and CEO. Dr. Camblong will transition to Executive Chairman of the Board, subject to election at the company's Annual General Meeting in June 2026.
Throughout 2025, Dr. Camblong has focused on positioning SOPHiA GENETICS for its next phase of growth. As Executive Chairman, he will continue as a full-time executive, concentrating on strategic initiatives, technology innovation, and long-term strategic direction.
"These executive changes reflect the Board's and Dr. Camblong's long-term succession planning," said Dr. Tomer Berkovitz, SOPHiA GENETICS Board Member and Managing Partner at aMoon Fund. "Jurgi has built a remarkable and unique company that has pioneered the application of AI in precision medicine, and we look forward to continuing our work with him, Ross, and the broader leadership team to transform patient care."
Ross Muken joined SOPHiA GENETICS in February 2021, prior to the Company's initial public offering, as Chief Financial Officer (CFO). In March 2023, he expanded his responsibilities to serve as joint CFO and Chief Operating Officer (COO), leading the Company's go-to-market organization, including Clinical Sales, BioPharma Diagnostics Sales, Sales Support, Marketing, Customer Experience, and Operations. In May 2024, Mr. Muken was promoted to company President, overseeing SOPHiA GENETICS' global business operations. In this role, he has played a central role in transforming the commercial organization and sales processes, reaccelerating business growth, and strengthening overall commercial execution.
"The last 15 years have been an incredible journey, realizing our vision to democratize data-driven medicine across more than 70 countries and 800 healthcare institutions. Having worked closely with Ross for five years, I've seen firsthand his exceptional strategic capabilities and operational leadership. I am confident he is the right person to lead the company through its next phase of growth and significantly expand our global impact," said Jurgi Camblong, SOPHiA GENETICS co-Founder.
"Jurgi has built something truly remarkable over the past 15 years, a unique company and technology platform that stands apart in the industry," said Ross Muken. "When I joined in 2021, I immediately recognized this was a category-defining company applying AI and cloud computing at unprecedented scale. Over these five years, working alongside Jurgi has been extraordinary. I've gained deep insights into our customers' needs, our technology's capabilities, and the exceptional talent of our team. I'm deeply honored to succeed Jurgi as CEO and look forward to continuing our partnership as he transitions to Executive Chairman."
Kevin Puylaert, the company's current Managing Director of EMEA, is appointed Chief Sales Officer effective January 2026. Kevin has been with SOPHiA GENETICS for more than 10 years, during which he has held multiple senior leadership roles, and his contributions have been instrumental to the company's growth.
Important Note Regarding Preliminary Unaudited Financial Results
SOPHiA GENETICS has not completed preparation of its financial statements for the fourth quarter or full year of 2025. The estimates presented in this news release for the fourth quarter and year ended December 31, 2025 are preliminary and unaudited and are thus inherently uncertain and subject to change as we complete our financial results for the fourth quarter of 2025. SOPHiA GENETICS is in the process of completing its customary year-end close and review procedures as of and for the year ended December 31, 2025, and there can be no assurance that final results for this period will not differ from these estimates. During the course of the preparation of SOPHiA GENETICS' consolidated financial statements and related notes as of and for the year ended December 31, 2025, we may identify items that could cause final reported results to be materially different from the preliminary financial estimates presented herein.
SOPHiA GENETICS plans to report its complete fourth quarter and full year 2025 financial results during its first earnings call of 2026 currently scheduled for March 3, 2026.
Liquid biopsy is emerging as a revolutionary technology, offering swift and precise diagnostics. It has the potential to significantly impact precision oncology by providing a non-invasive approach for cancer detection, monitoring, and treatment selection. However, liquid biopsy still faces challenges, including workflow standardization and broad adoption across the globe.
Join us for this webinar to learn more about the collaborative efforts of SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center, and AstraZeneca in enhancing global access to and adoption of MSK-ACCESS® powered with SOPHiA DDM™, aimed at addressing disparities in cancer care.
Key topics:
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.